The global thymopentin market size was valued at USD 150.50 million in 2024 and is expected to reach USD 217.32 million by 2032, at a CAGR of 4.70% during the forecast period

The market growth is largely fueled by the increasing prevalence of HIV and hepatocellular carcinoma, which is driving higher demand for effective therapeutic options and expanding the application of thymopentin in the pharmaceutical industry

Furthermore, rising healthcare expenditures, government support for research and development, and continued clinical trials are establishing thymopentin as a promising therapeutic peptide. These converging factors are accelerating the uptake of thymopentin-based treatments, thereby significantly boosting the industry's growth